Sign In
Buy VTRS
$17.56
-0.200 (-1.13%)
At Close: Jul 31, 2026
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
08:30am, Thursday, 19'th Mar 2026
Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful Near-Term Launches, Including Fast-Acting Meloxic
ISCV vs. VBR: Which Small Cap Value Approach is Right for Investors?
09:35am, Tuesday, 17'th Mar 2026
Sector exposure, yield, and fund size set these two small-cap value ETFs apart-see how these factors could impact your investment approach.
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research
11:11am, Thursday, 12'th Mar 2026
Generic drugmaker Viatris has settled a lawsuit brought by the family of Henrietta Lacks, a Maryland woman whose tissue samples were used without her permission to develop enduring cells for lucrat
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Wednesday, 04'th Mar 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
05:08pm, Thursday, 26'th Feb 2026
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris Inc (VTRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives
04:08pm, Thursday, 26'th Feb 2026
Total Revenue (Q4 2025): $3.7 billion, up 1% versus prior year, excluding Indore impact.Total Revenue (Full Year 2025): $14.3 billion, up 2% versus prior year,
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
12:46pm, Thursday, 26'th Feb 2026
VTRS beats Q4 estimates on 5% revenue growth, boosted by strong Brands sales and Greater China gains, while returning over $1B to shareholders in 2025.
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates
11:01am, Thursday, 26'th Feb 2026
Viatris (VTRS) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.54 per share a year ago.
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
11:01am, Thursday, 26'th Feb 2026
Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Stre
Viatris forecasts 2026 profit below estimates on India manufacturing woes
08:37am, Thursday, 26'th Feb 2026
Drugmaker Viatris forecast annual profit below analysts' expectations on Thursday, after a fire at one of its major plants in India disrupted operations.
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
06:59am, Thursday, 26'th Feb 2026
Reports Fourth-Quarter Total Revenues of $ 3.7B and Full-Year 2025 Total Revenues of $ 14.3B Meets or Exceeds 2025 Financial Guidance Across All Key Metrics[1] Returns More Than $1B to Shareholders in
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
06:55am, Thursday, 26'th Feb 2026
PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share an
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
06:59am, Wednesday, 25'th Feb 2026
FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administra
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics
10:16am, Monday, 23'rd Feb 2026
Evaluate the expected performance of Viatris (VTRS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
What's in Store for These 5 Medical Companies This Earnings Season?
10:11am, Monday, 23'rd Feb 2026
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
